Biotech Equity Crowdfunding Gets A Head Start Overseas
This article was originally published in Start Up
Can crowdfunding fill the biotech capital gap? In the US, new services are jockeying at the starting gate even though the government’s final rules won’t be ready soon, while in Europe the experiment has begun in earnest.
You may also be interested in...
While some aspects of the JOBS Act are up and running, many aren’t. At its annual meeting on capital formation for small business, SEC took the time to consider the remaining parts of the law that await rule making and to think beyond JOBS to other potential changes.
British biotech companies want the U.K. government to adopt a French method of funneling funds into the cash-strapped sector from private individuals in return for favorable rates of investment tax, on grounds that a version of France’s long-running Fonds Commun de Placement dans l'Innovation is needed for small-to-medium-sized biopharma companies in Britain to tap successfully into long-term seed capital.
With big Phase III failures heating debate about the amyloid hypothesis, small biotechs must convince investors that their early research is pointed in the right direction, and larger ones must design clinical trials with care. We profile four Alzheimer's-focused start-ups in this issue: AlzProtect, Axerion Therapeutics, Cognition Therapuetics and Galantos Pharma.